Longer-Term Results with Doravirine-Based Treatment for HIV

Doravirine, a new non-nucleoside reverse transcriptase inhibitor, was approved by the FDA in 2018 (NEJM JW Infect Dis Nov 2018), in part based on the 48-week results of the DRIVE-FORWARD study, in which doravirine had noninferior virologic efficacy to ritonavir-boosted darunavir. Now, the 96-week results of this manufacturer-sponsored trial are reported.

A total of 769 treatment-naive people with HIV were randomized to receive doravirine or ritonavir-boosted darunavir, each in combination with two nucleoside reverse transcriptase inhibitors. At week 96, 73% of the doravirine group and 66% of the darunavir group had HIV RNA levels <50 copies/mL. Treatment-emergent resistance occurred in only two of 383 people in the doravirine group (1%) and …